<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125472</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-GO1-006</org_study_id>
    <nct_id>NCT04125472</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1</brief_title>
  <official_title>Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide expanded access to lumasiran for adults and pediatric
      patients with Primary Hyperoxaluria Type 1 (PH1),
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choosing to participate in an expanded access program is an important personal decision. Talk
      with your doctor and family members or friends about deciding to join a research study. To
      learn more about this study, please have your doctor contact the study research staff using
      the Contacts provided. For general information, see the link provided in More Information.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Primary Hyperoxaluria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumasiran</intervention_name>
    <description>Lumasiran administered as a subcutaneous (SC) injection</description>
    <other_name>ALN-GO1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of Primary Hyperoxaluria Type1

          -  Meet the urine oxalate excretion requirements

        Exclusion Criteria:

          -  Clinically significant health concerns (with the exception of PH1)

          -  An estimated GFR of ≤ 45 mL/min/1.73m2 at screening

          -  Clinically significant abnormal laboratory results at screening

          -  Received an investigational agent within 30 days before the first dose of lumasiran or
             are in follow-up of another clinical study

          -  Previously or currently participating in lumasiran clinical study

          -  History of renal or liver transplant

          -  Women who are pregnant, planning a pregnancy, or breast-feeding or those of child
             bearing potential and not willing to use contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam EAP Hotline</last_name>
    <phone>(617) 715-0200</phone>
    <email>eap@alnylam.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Pīra'e</city>
        <country>French Polynesia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>French Polynesia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.alnylam.com/medical-professional-resources/early-access-program/lumasiran/</url>
    <description>Information on the Early Access Program for Lumasiran</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperoxaluria</keyword>
  <keyword>Primary Hyperoxaluria</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>RNA Therapeutic</keyword>
  <keyword>siRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

